Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 14/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20917566 | 0.90 | CACNA2D1 (0.44) | CACNA2D1SLC6A2 | |
| SCHEMBL19553335 | 0.85 | CACNA2D1 (0.44) | CACNA2D1KMT2ASLC7A5SLC6A2SLC6A4 | |
| SCHEMBL19553109 | 0.84 | CACNA2D1 (0.46) | CACNA2D1SLC7A5SLC6A2 | |
| SCHEMBL22367338 | 0.81 | CACNA2D1 (0.42) | CACNA2D1SLC7A5SLC6A2 | |
| SCHEMBL19553164 | 0.81 | CACNA2D1 (0.57) | CACNA2D1KMT2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19553166 | 0.81 | CACNA2D1 (0.57) | CACNA2D1KMT2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22367424 | 0.80 | CACNA2D1 (0.43) | CACNA2D1KMT2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22367305 | 0.80 | CACNA2D1 (0.49) | CACNA2D1SLC7A5SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL20600180 | 0.80 | CACNA2D1 (0.44) | CACNA2D1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19553665 | 0.80 | CACNA2D1 (0.46) | CACNA2D1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590140-B2 | Tetrahydropyrimidodiazepine and dihydropyridodiazepine compounds for treating pain and pain related conditions | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-03-17 | — | — | US | disclosed |
| US-20190144455-A1 | TETRAHYDROPYRIMIDODIAZEPINE AND DIHYDROPYRIDODIAZEPINE COMPOUNDS FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144455-A1 | TETRAHYDROPYRIMIDODIAZEPINE AND DIHYDROPYRIDODIAZEPINE COMPOUNDS FOR TREATING PAIN AND PAIN RELATED CONDITIONS | CACNA1G, CACNA1B, CACNA1D | CACNA2D1 12/4885KMT2A 1200/4885KCNA5 75/4885 |
| US-10590140-B2 | Tetrahydropyrimidodiazepine and dihydropyridodiazepine compounds for treating pain and pain related conditions | CACNA1G, CACNA1B, CACNA1D | CACNA2D1 12/4885KMT2A 1200/4885KCNA5 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.